Argeris Karabelas will become the new chairman of the board of directors of Human Genome Sciences next month, replacing William Haseltime after his retirement, the company said on Monday. Karabelas is a partner of investment firm Care Capital and has been a director of Human Genome Sciences since 2002. He holds a PhD in pharmacokinetics from the Massachusetts College of Pharmacy. In addition, Human Genome Sciences has promoted Craig Rosen to president and chief operating officer, from president for research and development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.